SFC Fluidics, a Breakthrough T1D Partner, Receives Breakthrough Device Designation
SFC Fluidics, a Breakthrough T1D partner, received a breakthrough device designation for its interoperable insulin delivery pod. How is it different? Find out here.
FDA Approves an Artificial Pancreas System for Children Aged 2-6 Years
The Food and Drug Administration (FDA) approved the Medtronic MiniMed 770G artificial pancreas system for use by children aged 2 to 6 with type 1 diabetes (T1D). It is the first marketed device that can automatically adjust insulin delivery based on continuous glucose monitoring (CGM) values for children aged 2-6 years.
Tandem Control-IQ Improves T1D Management in Children Ages 6 and Up
A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which automatically monitors and regulates blood-sugar levels—is safe and effective in children as young as age six with type 1 diabetes (T1D): Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology. The algorithm in the Control-IQ technology […]
Tandem Control-IQ—Now Authorized For Children
Tandem Diabetes announced FDA clearance of an expanded pediatric indication for the Tandem t:slim X2™ insulin pump with Control-IQ™ technology in children ages six and older.
Breakthrough T1D and Gore Invest in Development of Implantable Insulin Delivery System
PhysioLogic Devices, a Breakthrough T1D-funded company that is dedicated to transforming the treatment of type 1 diabetes (T1D), wants to develop the ThinPump™—a fully implantable automated insulin delivery system—in the next four years. We think it’s not only possible, but doable. PhysioLogic has two things going for it: Gore is well known for developing GORE-TEX […]
FDA Grants Breakthrough Device Status: iLet Bionic Pancreas
Earlier this week, Beta Bionics announced that the Food and Drug Administration (FDA) has granted breakthrough device designation to the company’s iLet Bionic Pancreas System, a wearable pocket-sized device used for blood sugar control in people with diabetes. The device can be adjusted to work as an insulin-only, glucagon-only or bi-hormonal artificial pancreas using both […]
FDA Authorizes a Second Artificial Pancreas System
The Food and Drug Administration (FDA) today authorized an algorithm that enables the second artificial pancreas system: The Control-IQ™ advanced hybrid closed loop technology. For now, the algorithm can be used with Tandem’s t:slim X2™ insulin pump and Dexcom’s G6 continuous glucose monitor (CGM). Though this is not the first algorithm approved for an artificial […]
This Stent is a Champion for Type 1 Diabetes Clinical Trials
Maribeth Stent was diagnosed with type 1 diabetes (T1D) in the fall of 1997. “It was right around my second birthday,” said Maribeth. She is now a senior coordinator of community engagement at Breakthrough T1D, and she took part in a clinical trial of a hybrid closed loop artificial pancreas system at Yale University in […]
Two T1D Technology Leaders Partnering to Drive Innovation and Choice
Two leading innovators in the type 1 diabetes (T1D) space have announced a collaborative partnership aimed at enabling those with T1D to select favorite devices, knowing they all work together, even if made by different companies. The nonprofit company Tidepool announce that it is partnering with leading pump manufacturer Medtronic to create an interoperable automated […]
A New AP System by Tandem Shows Key Time-in-Range Benefits
A new artificial pancreas system that both doses and takes away insulin is showing critical benefits in helping those with type 1 diabetes maintain more consistent, and healthier, glucose levels. Two studies, shared this weekend, showed that the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology by Tandem® Diabetes Care resulted in more […]
